Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma


Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.

Type Journal
ISBN 1556-1380 (Electronic) 1556-0864 (Linking)
Authors Barnet, M. B.; Zielinski, R. R.; Warby, A.; Lewis, C. R.; Kao, S.
Responsible Garvan Author Megan Barnet
Publisher Name Journal of Thoracic Oncology
Published Date 2018-01-01
Published Volume 12
Published Issue 12
Published Pages e1-e2
Status Published in-print
DOI 10.1016/j.jtho.2017.09.001
URL link to publisher's version